BIO-CANCER TREATMENT

Bio-Cancer Treatment, founded in 2000, is a clinical-stage biopharmaceutical company focused on the research and development of innovative biologics for the treatment of human malignancies and auto-immune disorders. The company's product candidate portfolio comprises BCT-100 and BCT-200, both pegylated recombinant human arginase 1 (pegArg1), are arginine depleting agents that retard tumor growth and ultimately cancer death. BCT-100 is currently in phase I clinical trial in the US for the treatment of arginine-auxotrophic solid cancers and phase II clinical trial in Hong Kong for the treatment of acute myeloid leukemia (AML). BCT-200, with modifications to the BCT-100 amino acid sequence, is at the pre-IND stage.